Dangerous Side Effects of Tequin

Jamie Sheller
Attorney
(866) 735-1102 Ext 475
Posted by Jamie ShellerMarch 23, 2006 2:03 PM

Bristol-Myers Squibb Co., has added warnings to the label for the antibiotic Tequin. The antibiotic is used to treat various infections, including pneumonia, bronchitis and kidney infections. Since the approval of Tequin in 1999, there have been cases of life-threatening events. The new labeling contains updated warnings reflecting information from continued reports of serious hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar). Also, the revised Tequin prescribing information includes a contraindication in diabetic patients due to the serious reports of hypoglycemia and hyperglycemia. Sheller, Ludwig and Badey is investigating claims of injury caused by Tequin.

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Comments for this article are closed.

Subscribe to InjuryBoard Philadelphia

InjuryBoard Philadelphia RSS Feeds

Keep up with the latest updates using your favorite RSS reader

Injury Board Philadelphia is brought to you by Sheller, P.C.

Legal Assistance Center

More Info
Sheller, P.C. (866) 735-1102 Ext 475 www.sheller.com
google
Personal Injury Lawyers Serving: Statewide Pennsylvania, Philadelphia, Norristown, Cheltenham, Chester, Drexel Hill, Folsom, Havertown, King of Prussia, Levittown, Radnor, Springfield, Swarthmore, West Chester, Willow Grove
1528 Walnut Street3rd Floor, Philadelphia, Pennsylvania 19102 [ Show Map ]
Better Business Bureau Accredited Business Confidential

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address